Throughout tumor formation, TIME simultaneously included CD8+ T-cell subgroups with definite features, and the proportion of CD8+ T-cell subpopulations in tumors had significant cancer heterogeneity and patient heterogeneity. This evidence concerns the gene CD8A and cancer.